A Medical Device Daily
Clarient (Munich, Germany) and Definiens (Aliso Viejo, California) reported that they established a strategic partnership to employ a series of image analysis platforms for Clarient's in-house research and development, and web-based customer portal PATHSiTE.
Under a five year collaborative agreement, Clarient and Definiens plan to develop and commercialize tools that will help to evaluate quantitative biomarkers that predict cancer treatment response to targeted therapies.
Ken Bloom, MD, Clarient's chief medical officer, said, "The availability of image analysis tool sets is essential as we enter the age of personalized medicine. Many of the assays in development assess several intracellular processes simultaneously, and it is critical that we develop algorithms that localize and quantify key markers. We now have the ability to provide a number of image analysis tools across a wide range of technologies to help facilitate biomarker assessment for our biopharma clients in the clinical marketplace."
Bloom added, "The Definiens agreement provides us with access to a team of scientists that have extensive experience in software development and biomarker analysis for applications in the life sciences."
Clarient processes large numbers of tissue samples for biomarkers from customers worldwide for both clinical decision-making and biopharmaceutical development. These tissue samples are then converted into high-resolution digital images that are managed and analyzed over Clarient's PATHSiTE portal.
The partnership with Definiens involves seamlessly integrating a wide range of image analysis tools into Clarient's existing infrastructure.
In other agreements/contracts news:
• Luminex (Austin, Texas) and BD (Franklin Lakes, New Jersey), through its BD Diagnostics-TriPath platform, reported the signing of a development and supply agreement. Under the terms of the agreement, BD Diagnostics-TriPath will develop, market and sell new biomarker-based diagnostic tests for certain cancers using Luminex's multiplexing xMAP Technology platform.
• GE Healthcare (Chalfont St. Giles, England) reported a distribution and technology collaboration agreement with Living Independently Group (New York), a provider of telecare and passive monitoring systems used to assist in the care of seniors.
GE will distribute and co-market Living Independently's QuietCare products globally. The companies will use GE's Global Research Center and its advanced work in clinical parameters and monitoring algorithms to drive innovation in the field of remote patient monitoring and diagnostics. GE said it would also take a minority ownership stake in Living Independently. Financial terms of the agreement were not disclosed.
• Block Imaging International (Lansing, Michigan) has formed a strategic partnership with Dicom Solutions (Irvine, California) and will now carry a new line of medical imaging digital solutions. Block Imaging will provide its customers with PACS, RIS, DICOM to CD, CR and archive solutions from Dicom Solutions. Dicom Solutions will in turn offer its customers Block Imaging's inventory of refurbished and pre-owned medical imaging equipment, such as MRI, CT and DR.
• Z-Medica (Wallingford, Connecticut) said that it has been awarded a $2.9 million contract from the U.S. Navy and Marine Corps to fund large-scale human studies on stopping bleeding in penetrating wounds, using the company's new QuikClot Combat Gauze. The U.S. Department of Defense Committee on Tactical Combat Casualty Care recently selected QuikClot as the first-line hemorrhage treatment for tourniquet-resistant wounds for all branches of the U.S. military.
QuikClot combines surgical gauze with an inorganic material that stops arterial and venous bleeding in seconds.
• Medtral New Zealand (Auckland) reported a strategic partnership with Global Medical Conexions (GMCx, San Francisco). GMCx maintains an International Select Provider Organization (ISPO) consisting of the highest quality physician and hospital partners in the healthcare field and will add Medtral hospitals to its network.
"This strategic alliance will serve the interests of both organizations because the addition of medical travel to New Zealand opens opportunities for Medtral to expand its client base while providing our clients with the best and most attractively priced options for medical travel," said Bob Repke, president of GMCx.
Medtral New Zealand services include: travel, accommodation, hospital procedures, and post-operative care at New Zealand's premier private medical facilities.
• Fletcher-Flora Health Care Systems (Anaheim, California) said that Florida Cancer Specialists (Fort Myers, Florida) has signed a master license agreement to implement its FFlex eSuite laboratory information system (LIS) solution in their multi-facility operation.
Florida Cancer Specialists wanted LIS technology to help integrate 22 remote lab and facilitate further expansion.